Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Infant Bacterial Therapeutics AB ( ($SE:IBT.B) ) just unveiled an announcement.
Infant Bacterial Therapeutics AB announced that the results from their pivotal Phase III trial, The Connection Study, will be presented at the ESPGHAN 2025 conference in Helsinki. The study evaluates the efficacy of IBP-9414, a product designed to prevent NEC in preterm infants, and its findings could significantly impact the treatment of this life-threatening condition, potentially enhancing IBT’s position in the pediatric biotherapeutics market.
More about Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) operates in the biopharmaceutical industry, focusing on developing treatments for diseases affecting infants. Their primary product, IBP-9414, is a Live Biotherapeutic Product aimed at preventing necrotizing enterocolitis (NEC) and reducing mortality in preterm infants.
Average Trading Volume: 20,902
Current Market Cap: SEK788.1M
Learn more about IBT.B stock on TipRanks’ Stock Analysis page.